Compass Therapeutics, Inc. — Director's Dealing 2020

Jun 24, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (NONE)
CIK: 0001738021
Period of Report: 2020-06-19

Reporting Person: ORBIMED ADVISORS LLC (Director, 10% Owner)
Reporting Person: OrbiMed Capital GP V LLC (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-19	Common Stock	P	1455132	$5.00	Acquired	12714404	Direct

Footnotes

F1: These shares are held of record by OrbiMed Private Investments V-KA, LP ("OPI V-KA"). OrbiMed Capital GP V LLC ("OrbiMed GP V") is the general partner of OPI V-KA and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP V. By virtue of such relationships, OrbiMed GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares held by OPI V-KA and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V-KA.

F2: This report on Form 4 is jointly filed by OrbiMed Advisors and OrbiMed GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon ("Gordon"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.